PRESS RELEASE published on 11/04/2025 at 11:38, 5 months 27 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research initiates coverage on MaaT Pharma SACA with a BUY rating and EUR 17 price target. MaaT Pharma focuses on microbiome-based therapies for oncology, with high clinical impact and late-stage pipeline Oncology BUY Rating Clinical-stage Biotechnology MaaT Pharma SACA Microbiome-based Therapies
BRIEF published on 11/04/2025 at 07:35, 5 months 27 days ago MaaT Pharma Third Quarter 2025 Financial Results and Financing Update Financial Results MaaT Pharma European Medicines Agency Xervyteg® Clinigen Partnership
PRESS RELEASE published on 11/04/2025 at 07:30, 5 months 27 days ago Inside Information / News release on accounts, results MaaT Pharma reports Q3 2025 financial results, secured financing, and partnership updates. Cash position of €22.4 million. Revenues increased by 45% year-over-year Revenues Financing Partnership MaaT Pharma Q3 2025
BRIEF published on 10/13/2025 at 14:52, 6 months 19 days ago Crossing of Thresholds by Invus Public Equities in MAAT PHARMA Voting Rights Crossing Thresholds Transfer Of Shares MaaT Pharma Invus Public Equities
BRIEF published on 10/06/2025 at 14:59, 6 months 26 days ago Symbiosis LLC Reduces Stake in MAAT PHARMA Voting Rights Crossing Thresholds Transfer Of Shares MaaT Pharma Symbiosis LLC
BRIEF published on 09/17/2025 at 07:35, 7 months 14 days ago MaaT Pharma unveils its 2025 half-year results Revenue Growth Half-year Results EIB Financing MaaT013 Efficiency Clinigen Agreement
PRESS RELEASE published on 09/17/2025 at 07:30, 7 months 14 days ago Inside Information / Information on annual revenues MaaT Pharma presents positive Half Year 2025 Results with promising data from Phase 3 trial of MaaT013 in aGvHD. Company strengthens position with partnerships and financing Partnerships Phase 3 Trial Half Year Results MaaT Pharma AGvHD
BRIEF published on 07/28/2025 at 07:35, 9 months 4 days ago MaaT Pharma Secures €37.5 Million Loan to Boost Hemato-Oncology Programs Clinical Development EIB Loan Hemato-oncology Microbiome Therapy Xervyteg® Approval
PRESS RELEASE published on 07/28/2025 at 07:30, 9 months 4 days ago Inside Information / Other news releases MaaT Pharma secures €37.5 million loan from the European Investment Bank to advance clinical programs in Hemato-Oncology. Funding supports late-stage assets Xervyteg® and MaaT033 European Investment Bank Clinical Programs Loan MaaT Pharma Hemato-oncology
BRIEF published on 06/24/2025 at 20:05, 10 months 7 days ago MaaT Pharma General Meeting: Results and Appointments Kepler Cheuvreux Resolutions General Assembly MaaT Pharma Appointment Of President
Published on 05/02/2026 at 00:00, 21 minutes ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 21 minutes ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/01/2026 at 22:30, 1 hour 51 minutes ago Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 1 hour 51 minutes ago Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 22:30, 1 hour 51 minutes ago Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.
Published on 05/01/2026 at 19:23, 4 hours 58 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 6 hours 36 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 7 hours ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 4 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 5 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 5 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 6 hours ago Minutes of the Combined General Meeting held on April 30, 2026
